Evaluation of frequency and the attacks features of patients with colchicine resistance in FMF  by Cetin, Gozde Yildirim et al.
r e v b r a s r e u m a t o l . 2 0 1 4;5 4(5):356–359
REVISTA BRASILEIRA DE
REUMATOLOGIA
w w w.reumato logia .com.br
Original article
Evaluation  of  frequency  and  the  attacks  features  of
patients with  colchicine  resistance  in FMF
Gozde Yildirim Cetina,∗, Ayse Balkarli b, Ali Nuri Öksüza, Gezmis¸ Kimyonc,
Yavuz  Pehlivanc, Ozlem Orhana, Bunyamin Kisacikc, Veli Cobankarab,
Hayriye Sayarlioglud, Ahmet Mesut Onatc, Mehmet Sayarlioglud
a Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey
b Pamukkale University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Denizli, Turkey
c Gaziantep University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Gaziantep, Turkey
d Ondokuz Mayis University, School of Medicine, Department of Internal Medicine, Division of Nephrology, Samsun, Turkey
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 26 August 2013
Accepted 17 March 2014
Available online 20 August 2014
Keywords:
Familial Mediterranean fever
Colchicine resistance
Treatment
Depression
a  b  s  t  r  a  c  t
Introduction: Colchicine is the mainstay for the treatment of FMF, which is an auto-
inﬂammatory disease mainly with relapsing polyserositis. Despite daily doses of 2 mg  or
more  each day, approximately 5% to 10% of the patients continue to suffer from its attacks.
In  this study, we aimed to investigate the depression and attack features in patients with
FMF who have colchicine resistance (CR).
Patients e Methods: CR was deﬁned for FMF patients with 2 or more attacks within the last
6  months period while using 2 mg/day colchicine. Eighteen patients (9 Female/9 Male) were
enrolled into the CR group and 41 patients were enrolled into the control group (12 Male/29
Female). Demographic, clinical e laboratory ﬁndings, treatment adherence, and the Beck
Depression Inventory (BDI) scores were evaluated.
Results: The age of onset of FMF was signiﬁcantly lower in the CR group (12.3 yrs vs. 16.9 yrs,
P  = 0.03). Disease duration was longer in the CR group (P = 0.01). Abdominal and leg pain due
to  exercise were signiﬁcantly more frequent in the CR group versus controls (83% vs. 51%;
P  = 0.02 e 88% vs. 60%; P = 0.04, respectively). Patients with BDI scores over 17 points were
more  frequent in the CR group compared to controls (50% vs. 34.1%; P < 0.001).
Discussion: We found that: (1) the age of disease onset was lower and (2) the disease duration
was  longer in CR group. Pleuritic attacks, hematuria e proteinuria were more frequent in CR
patients. We  propose that depression is an important factor to consider in the susceptibilityto  CR.
© 2014 Elsevier Editora Ltda. All rights reserved.DOI of original article: http://dx.doi.org/10.1016/j.rbr.2014.03.022.
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Avaliac¸ão  da  frequência  e  aspectos  dos  ataques  de  pacientes  com
resistência  à  colchicina  em  febre  familiar  do  Mediterrâneo  (FFM)
Palavras-chave:
Febre familiar do Mediterrâneo
Resistência à Colchicina
Tratamento
Depressão
r  e  s  u  m  o
Introduc¸ão: Colchicina é a viga-mestra para o tratamento de FFM, que é uma doenc¸a autoin-
ﬂamatória com polisserosite recidivante como principal manifestac¸ão. Apesar de doses
diárias de 2 mg ou mais/dia, aproximadamente 5%-10% dos pacientes continuam a sofrer de
seus  ataques. Neste estudo, objetivamos investigar os aspectos da depressão e dos ataques
em  pacientes com FFM apresentando resistência à colchicina (RC).
Pacientes e Métodos: Em pacientes com FFM, RC foi deﬁnida como dois ou mais ataques
nos  últimos seis meses, quando em medicac¸ão com colchicina 2 mg/dia. Dezoito pacientes
(nove mulheres e nove homens) foram recrutados no grupo RC e 41 pacientes no grupo
de  controle (29 mulheres/12 homens). Foram avaliados os achados demográﬁcos, clínicos e
laboratoriais, a ﬁdelidade ao tratamento e os escores do Beck Depression Inventory (BDI).
Resultados: A idade de surgimento da FFM foi signiﬁcativamente menor no grupo RC
(12,3  anos vs. 16,9 anos, P = 0,03). A durac¸ão da doenc¸a foi maior no grupo RC (p = 0,01).
Dores abdominais e nas pernas em decorrência do exercício foram signiﬁcativamente mais
frequentes no grupo RC versus controles (83% vs. 51%; p = 0,02 e 88% vs. 60%; p = 0,04, res-
pectivamente). Pacientes com escores BDI > 17 pontos foram mais frequentes no grupo RC
versus controles (50% vs. 34,1%; p < 0,001).
Discussão: Veriﬁcamos que: (1) a idade do surgimento da doenc¸a foi mais baixa e (2) a durac¸ão
da  doenc¸a foi maior no grupo RC. Ataques pleuríticos, hematúria e proteinúria foram mais
frequentes em pacientes com RC. Propomos que a depressão é fator importante a ser levado
em  considerac¸ão na sensibilidade à RC.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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amilial Mediterranean fever (FMF) is a hereditary and an
uto-inﬂammatory disease predominantly characterized by
epeated attacks of fever, abdominal pain, pleuritic chest
ain, arthritis, and erysipelas-like erythema. The disease is
ost prevalent among non-Ashkenazi Jews, Arabs, Turks,
nd Armenians.1 The pathogenesis is mainly based on the
bsence or insufﬁciency of pyrin production, which is a
eptide involved in the inﬂammatory cascade that inhibits
omplement 5a (C5a). The main mechanisms that trigger FMF
ttacks have not been established. Colchicine is still the main-
tay in the treatment of the disease. It completely or partially
revents FMF  attacks and subsequent reactive amyloidosis
hat is regarded as the most dangerous complication of FMF.2
Interestingly, colchicine resistance (CR) is prevalent in
early 10% of the FMF  patients. The attack frequency or inten-
ity may go on with similar or diminished frequency and
everity. The CR patients could be divided into complete or
artially non-responders. Many  factors might be involved in
he CR, including genetic predisposition as well as environ-
ental and psychiatric conditions. Still, little is known about
he absolute etiology of CR in FMF  patients. Treatment adher-
nce and potential reasons including demographical factors,
ocio-economic status, clinical and laboratory factors, and
sychiatric dynamics are thought to be contributing factors.
The Beck Depression Inventory (BDI) was developed by
eck and colleagues (1979) and adapted to Turkish by Hisli
1988). The BDI is a self-report scale of 21 items measuring the
motional, somatic, cognitive, and motivational symptomsexhibited in depression. The scale is not designed to diag-
nose depression but to objectively determine the severity of
depressive symptoms. Correlation coefﬁcients between the
English and Turkish versions of the scale were calculated as
0.81 and 0.73 (language validity); split half reliability was 0.74,
and criterion-related validity with MMPI-D (Minnesota Mul-
tiphasic Personality Inventory) was 0.63. The BDI  scores ≥ 17
were reported to discriminate depression that might require
treatment with more  than 90% accuracy. The score of each
item ranges from 0 to 3, and the depression score is obtained
by adding the score of each item. The highest obtainable score
is 63.3,4
As a consequence, different therapeutic strategies are
ongoing to limit CR in FMF  patients. In this study, we aimed
to investigate the depression and attack features in patients
with FMF who have the CR.
Patients  and  methods
The study group was composed of 59 FMF  patients with 18
CR (9 female / 9 male) and 41 (12 male / 29 female) complete
colchicine responders. Patients having other accompanying
diseases including infections, malignancies, autoimmune or
metabolic diseases and patients who were diagnosed for
depression previously and under-treatment with antidepres-
sants were excluded. The diagnosis was checked one more
time through the re-questioning of the patients in accordance
with the Livneh criteria of FMF.
CR was deﬁned as two or more  FMF attacks in a six-month
period following a twelve-month regular therapy. Patients
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Table 1 – Demographic features of CR group and control group.
CR Group (n = 18) Control Group (n = 41) p values
Current age (age ± SD) 30.1 ± 10,5 28.2 ± 9.3 0.5
Gender (F/M) 9/9 29/12 0.12
Monthly income over 1000 TL 5 (27.7%) 10 (24.3%) 0.78
# of married subjects 5 (27.7%) 22 (53.6%) 0.59
Educational status (undergraduates) 5(27.7%) 9 (21.9%) 0.62
# of unemployed subjects 2 (11.1%) 8 (19.5%)
# of kids (number ± SD) 1 ± 1.5 0.9 ± 1.3 0.8
Subjects with family history of FMF 13 (72.2%) 27 (65.8%) 0.6
Age of FMF Diagnosis 20.6 ± 8.6 21.9 ± 10 0.6
Time between onset and diagnosis (months) 92 59.3 0.2
Diseases duration (months) 212 133 0.01CR, Colchicum resistant; TL, Turkish Lira.
with ≤ 1 FMF  attack within the six months or without any
attacks over the twelve months were randomized into the con-
trol group. Patients in the colchicine resistance group were
using 2 mg/day and higher doses, and in the control group
patients were using colchicine below the doses of 2 mg/day.
The demographic data, adherence to treatment, clinical and
attack features of the disease including the leg pain and
amyloidosis, laboratory ﬁndings, and BDI scores, alcohol, and
narcotic usage were recorded. A BDI score > 17 was considered
signiﬁcant for severe depression that requires treatment.
The age of disease onset as well as diagnosis and the
time period from symptoms to diagnosis were carefully
questioned. The demographic data included socio-economic
features such as monthly income, education and literacy, mar-
ital status, number of children, and employment. Patients
were compared by the minimum wage  in our country for
their economic status. Concerning the educational status,
post-graduate patients were compared with each other. Urine
analyses were assessed with a dipstick during attacks and
were collected from ﬁles.
The local ethical committee approved the study protocol
and all the participant consent forms were collected. Stu-
dent’s t test and one-way ANOVA were used for comparison
of averages. Pearson’s correlation analyses were performed to
evaluate other factors. P value of < 0.05 was accepted as statis-
tically signiﬁcant.
Results
While CR patients were regularly implementing the treatment
protocol during the 6-month follow-up, 40% of the patients
in control group were misusing the drugs. Baseline demo-
graphic features of both groups are demonstrated in Table 1.
There was no statistically signiﬁcant difference between the
groups concerning the monthly income, educational and mar-
ital status, number of kids, and employment. Distribution of
the patients with family history of FMF  was similar. Disease
onset age was signiﬁcantly lower in CR group in contrast to
the controls (12.3 years and 16.9 years; p = 0.03) and disease
duration was signiﬁcantly longer in CR group (212 months and
133 months; p = 0.01). There were similar results concerning
the time from disease onset to diagnosis, and the difference
was not signiﬁcant between the groups. When we comparedthe accompanying complaints during the attacks, pleuritic
chest pain, erysipelas-like erythema and effort associated, leg
pain was signiﬁcantly more  frequent in CR group (83% and
51% p = 0.02; 16.6% and 2.4% p = 0.04; 88% and 60% p = 0.04;
respectively). Moreover, transient proteinuria and hematuria
were signiﬁcantly more  frequent in CR group (p = 0.006). There
was not a valuable difference between the groups concerning
abdominal pain and arthritis (Table 2). There were no alco-
hol or narcotics history among the groups. The number of
patients with amyloidosis in both groups was similar (Table 2).
There was no renal insufﬁciency in both groups. Patients with
BDI scores over 17 points were more  frequent in the CR group
compared to the controls (50% vs 34.1%; p < 0.001).
Discussion
This prospectively designed study attempts to evaluate the
factors that may lead to CR among the FMF  patients. Disease
onset age was signiﬁcantly lower in CR group in contrast to
the control, and disease duration was signiﬁcantly longer in
CR group. Questionnaire results showed that patients in CR
group were receiving their drugs regularly under full drug
compliance. Patients with infrequent attacks forgot to take
the colchicine. Additionally, there were no alcohol or narcotics
history among the CR patients. In fact, the main triggering
etiological factors behind CR are not known. In the previous
study, Lidar et al. found that patients with severe FMF  prog-
nosis had more  CR.6 These ﬁndings are in good agreement
with our study. Obviously, patients with long disease dura-
tion, high BDI scores, were signiﬁcantly more  frequent in the
CR group. And attacks in CR group were more  severe than
control group. When we  compared the accompanying com-
plaints during the attacks, pleuritic chest pain, erysipelas-like
erythema, and effort associated leg pain were more frequent
in CR group. Moreover, proteinuria and hematuria presence
during the attacks were more  frequent in CR group. Also Lidar
et al. demonstrated that the abdominal attack, chest pain, and
arthritis were more  frequent and severe in CR group, while
erysipelas-like erythema attacks were similar in both groups.
The presence of depression could increase the frequency of
FMF  attacks or the combination of frequent FMF attacks and
inﬂammatory pain might cause depression. The activity of
serotonergic inﬂammatory cascade has been speculated to
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Table 2 – Symptomatic features of all patients.
CR Group (n = 18) Control Group (n = 41) p values
Abdominal attack 16 (88.8%) 39 (95.1%) 0.38
Joint attack 14 (77.7%) 30 (73.1%) 0.7
Chest attack 15 (83.3%) 21 (51.2%) 0.02
Erysipela-like erythema 3 (16.6%) 1 (2.4%) 0.04
Effort associated leg pain 15 (83.3%) 25 (60.9%) 0.04
Presence of transient hematuria and proteinuria during the attacks 8 (44.4%) 5 (12.1%) 0.006
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Mediators Inﬂamm. 2002;11:265–7.
12. Erken E, Ozer HT, Gunesacar R. Plasma interleukin-10 and
interleukin-12 levels in patients with familial Mediterranean
fever. Rheumatol Int. 2006;26:862–4.of patients with amyloidosis 
of family members with amyloidosis 
rovoke the FMF  attacks.7 It was demonstrated that initiat-
ng selective serotonin reuptake inhibitors (SSRI) decreases
he frequency of FMF attacks with CR.8 Accordingly, it was
hown that stress factors facilitate depression and increase
he secretion of inﬂammatory cytokines.9 There are studies
rguing the role of depression in the severity of FMF and that
epression treatment also diminishes the number of attacks.
hese ﬁndings reveal the role of depression in CR.8
Increases in inﬂammation can affect the pathophysi-
logy of the depression.8 In cytokine based FMF  studies,
lasma concentrations of interleukin-2 (IL), IL-12, IL-18 and
umor necrosis alpha (TNF-)  were elevated in depressive
atients.10,11 The pro-inﬂammatory cytokine, IL-12, was ele-
ated both during the attacks and in the attack free period,
ontrasting healthy control studies.12 In addition to IL-12
ecretion, cytotoxic T cells IL-2, IFN gamma,  and TNF-alpha
lso increased in FMF  patients. These cytokines were elevated
oth in FMF  and depression. Our study has a limitation for
he MEFV mutations of the patients that didn’t hold for all
f the patients enrolled into the study. But our aim was the
nvestigation of other factors affecting CR.
Consequently, we can argue that depression is an impor-
ant reason among the factors that may lead to CR. Consistent
ith previous studies, we have found out the CR patients’
epression ﬁndings are more  severe than the controls. Cli-
icians should consider the initiation of SSRI in colchicum
esistant patients. We  found that disease onset age was lower
nd disease duration was longer. In addition, pleuritis attacks,
ransient microscopic hematuria, and proteinuria were more
requent in CR patients during attack episodes. Further large-
cale screening is required.
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